Literature DB >> 22156962

Perinatal outcomes, mitochondrial toxicity and apoptosis in HIV-treated pregnant women and in-utero-exposed newborn.

Sandra Hernàndez1, Constanza Morén, Marta López, Oriol Coll, Francesc Cardellach, Eduard Gratacós, Oscar Miró, Glòria Garrabou.   

Abstract

OBJECTIVE: Highly active antiretroviral therapy (HAART) has decreased the risk of HIV mother-to-child transmission. However, HIV and HAART have been associated with adverse perinatal outcome. HAART has been associated with mitochondrial dysfunction in nonpregnant adults, and HIV, additionally, to apoptosis. We determined whether mitochondrial toxicity and apoptosis are present in HIV-pregnant women and their newborns and could be the basis of adverse pregnancy outcome.
DESIGN: Single-site, cross-sectional, controlled observational study without intervention.
METHODS: We studied mitochondrial and apoptotic parameters in mononuclear cells from maternal peripheral blood and infant cord blood at delivery in 27 HIV-infected and treated pregnant women, and 35 uninfected controls and their infants, to correlate clinical outcome with experimental findings: mitochondrial number (CS), mtDNA content (ND2/18SrRNA), mitochondrial protein synthesis (COX-II/V-DAC), mitochondrial function (enzymatic activities) and apoptotic rate (caspase-3/β-actin).
RESULTS: Global adverse perinatal outcome, preterm births and small newborn for gestational age were significantly increased in HIV pregnancies [odds ratio (OR) 7.33, 5.77 and 9.71]. Mitochondrial number was unaltered. The remaining mitochondrial parameters were reduced in HIV mothers and their newborn; especially newborn mtDNA levels, maternal and fetal mitochondrial protein synthesis and maternal glycerol-3-phosphate + complex III function (38.6, 25.8, 13.6 and 31.2% reduced, respectively, P < 0.05). All materno-fetal mitochondrial parameters significantly correlated, except mtDNA content. Apoptosis was exclusively increased in infected pregnant women, but not in their newborn. However, adverse perinatal outcome did not correlate mitochondrial or apoptotic findings.
CONCLUSIONS: Transplacental HAART toxicity may cause subclinical mitochondrial damage in HIV-pregnant women and their newborn. Trends to increased maternal apoptosis may be due to maternal-restricted HIV infection. However, we could not demonstrate mitochondrial or apoptotic implication in adverse perinatal outcome.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22156962     DOI: 10.1097/QAD.0b013e32834f3232

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  17 in total

1.  Maternal post-absorptive leucine kinetics during late pregnancy in US women with HIV taking antiretroviral therapy: a cross-sectional pilot study.

Authors:  W Todd Cade; Gautam K Singh; Mark R Holland; Dominic N Reeds; E Turner Overton; Nancy Cibulka; Karen Bahow; Rachel Presti; Andrea Stephens; Alison G Cahill
Journal:  Clin Nutr ESPEN       Date:  2015-08-01

2.  Elevated Blood Mitochondrial DNA in Early Life Among Uninfected Children Exposed to Human Immunodeficiency Virus and Combination Antiretroviral Therapy in utero.

Authors:  Abhinav Ajaykumar; Mayanne Zhu; Fatima Kakkar; Jason Brophy; Ari Bitnun; Ariane Alimenti; Hugo Soudeyns; Sara Saberi; Arianne Y K Albert; Deborah M Money; Hélène C F Côté
Journal:  J Infect Dis       Date:  2021-02-24       Impact factor: 5.226

3.  Quantification of mitochondrial toxicity in HIV-infected individuals by quantitative PCR compared to flow cytometry.

Authors:  Thor A Wagner; Chen-Han Lin; Nicole H Tobin; Hélène C F Côté; Derek D Sloan; Keith R Jerome; Lisa M Frenkel
Journal:  Cytometry B Clin Cytom       Date:  2012-10-08       Impact factor: 3.058

4.  Risk of intrauterine growth restriction among HIV-infected pregnant women: a cohort study.

Authors:  M López; M Palacio; A Goncé; S Hernàndez; F J Barranco; L García; M Loncà; J O Coll; E Gratacós; F Figueras
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-08-09       Impact factor: 3.267

5.  Paternal involvement and fetal morbidity outcomes in HIV/AIDS: a population-based study.

Authors:  Amina P Alio; Alfred K Mbah; Krupa Shah; Euna M August; Sharon Dejoy; Korede Adegoke; Phillip J Marty; Hamisu M Salihu; Muktar H Aliyu
Journal:  Am J Mens Health       Date:  2013-08-02

6.  Mitochondrial DNA Instability Is Common in HIV-Exposed Uninfected Newborns.

Authors:  Audrey Monnin; Valérie Desquiret-Dumas; Nicolas Méda; David Goudenège; Céline Bris; Chipepo Kankasa; Mandisa Singata-Madliki; Thorkild Tylleskar; Vincent Procaccio; Nicolas Nagot; Philippe Van de Perre; Pascal Reynier; Jean-Pierre Molès
Journal:  J Clin Med       Date:  2021-05-28       Impact factor: 4.241

7.  Evidence of Subclinical mtDNA Alterations in HIV-Infected Pregnant Women Receiving Combination Antiretroviral Therapy Compared to HIV-Negative Pregnant Women.

Authors:  Deborah M Money; Emily C Wagner; Evelyn J Maan; Tessa Chaworth-Musters; Izabelle Gadawski; Julie E van Schalkwyk; John C Forbes; David R Burdge; Arianne Y K Albert; Zoe Lohn; Hélène C F Côté
Journal:  PLoS One       Date:  2015-08-06       Impact factor: 3.240

Review 8.  Mitochondrial toxicity in human pregnancy: an update on clinical and experimental approaches in the last 10 years.

Authors:  Constanza Morén; Sandra Hernández; Mariona Guitart-Mampel; Glòria Garrabou
Journal:  Int J Environ Res Public Health       Date:  2014-09-22       Impact factor: 3.390

9.  HIV protease inhibitor use during pregnancy is associated with decreased progesterone levels, suggesting a potential mechanism contributing to fetal growth restriction.

Authors:  Eszter Papp; Hakimeh Mohammadi; Mona R Loutfy; Mark H Yudin; Kellie E Murphy; Sharon L Walmsley; Rajiv Shah; Jay MacGillivray; Michael Silverman; Lena Serghides
Journal:  J Infect Dis       Date:  2014-07-16       Impact factor: 5.226

10.  Mitochondrial toxicity and caspase activation in HIV pregnant women.

Authors:  Sandra Hernandez; Constanza Moren; Marc Catalán-García; Marta Lopez; Mariona Guitart-Mampel; Oriol Coll; Laura Garcia; Jose Milisenda; Angela Justamante; Josep Maria Gatell; Francesc Cardellach; Eduard Gratacos; Òscar Miro; Gloria Garrabou
Journal:  J Cell Mol Med       Date:  2016-08-30       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.